B+
Bull case
25%
Probability
Target price
$6.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CLOV
Clover Health InvestmentsCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+68.0
Score
AI commentary
The company-source evidence is positive after the Q2 report and guidance raise [#SEC-8K-2026-08-05]. MarketBeat's earnings page showed CLOV at $4.76, up 2.15% on August 8, and linked coverage reporting a roughly 20% post-print surge tied to the Q2 beat and guidance raise [MarketBeat](https://www.marketbeat.com/earnings/reports/2026-8-5-clover-health-investments-corp-stock/). Canaccord's latest identified target action was positive but pre-print; no later analyst revisions were found. Direct MA comparators improve the peer context, but this remains a positive monitoring view rather than a high-conviction call.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-05eventQ2 2026 results and raised FY2026 guidanceHigh impact
Clover reported $743 million of Q2 revenue, $28 million of GAAP net income, 157,309 Medicare Advantage members, and $41 million of adjusted EBITDA, while raising full-year revenue, gross profit, EBITDA, membership, and GAAP-income guidance [#SEC-8K-2026-08-05].
2026-11-06catalystPost-print follow-through against the raised guideHigh impact
Near-term momentum depends on whether investors continue to credit the raised outlook and whether subsequent results validate medical-cost, membership, gross-profit, EBITDA, and GAAP-profit trends [#SEC-8K-2026-08-05].
2027-01-01catalystCohort maturation and 4.5-Star payment-year economicsHigh impact
Management cited stronger cohort development, continued clinical engagement, and the added flexibility of a 4.5-Star payment year as support for its 2027 outlook [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology